Macquarie Group’s UroGen Pharma URGN Stock Holding History

Macquarie Group’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-959	Closed	-$8	–	2630
2022 Q1	$8	Hold	959	–	–	﹤0.01%	2542
2021 Q4	$9K	Hold	959	–	–	﹤0.01%	2525
2021 Q3	$16K	Hold	959	–	–	﹤0.01%	2491
2021 Q2	$15K	Hold	959	–	–	﹤0.01%	2422
2021 Q1	$19K	Sell	959 -163	-15%	-$3.46K	﹤0.01%	2304
2020 Q4	$20K	Hold	1,122	–	–	﹤0.01%	2223
2020 Q3	$22K	Hold	1,122	–	–	﹤0.01%	2150
2020 Q2	$29K	Buy	+1,122	New	+$27.4K	﹤0.01%	2068
2018 Q1	–	Sell	-300	Closed	-$11K	–	2366
2017 Q4	$11K	Buy	+300	New	+$10.7K	﹤0.01%	2253

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Macquarie Group's URGN Position: Q2 2022 in Review

Macquarie Group sold out of UroGen Pharma (URGN) in Q2 2022, closing a stake of 959 shares — an estimated $8 sold.

Macquarie Group first reported a position in URGN in Q4 2017 and held it in 9 quarters. The position peaked at $29K in Q2 2020. 65 funds tracked by Wall St. Rank hold URGN as of Q2 2022.

Macquarie Group reported no remaining UroGen Pharma position as of Q2 2022 after selling out during the quarter.
Macquarie Group sold 959 UroGen Pharma shares in Q2 2022, an estimated $8.
Macquarie Group first reported a position in UroGen Pharma in Q4 2017 and held it in 9 quarters.
Macquarie Group's UroGen Pharma position peaked at $29K in Q2 2020.
65 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2022.

Based on Macquarie Group's 13F filing for Q2 2022, filed 15 Aug 2022.